{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-22-000039","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2022-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.063238+00:00","generated_at":"2026-06-25T00:56:09.295294+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Allogene shareholders elect directors, approve authorized share increase to 400M","bullets":["Four Class I directors elected: Elizabeth Barrett, Arie Belldegrun, David Bonderman, David Chang.","Advisory vote on executive compensation passed: 103,325,400 for, 7,596,094 against.","Authorized common shares increased from 200M to 400M; amendment filed June 16, 2022.","Stock option exchange program approved: 77,394,629 for, 33,536,201 against.","Ernst & Young ratified as auditor for FY2022: 125,514,754 for, 49,928 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-22-000039","json":"https://secwatch.observer/filing/0001737287-22-000039.json","markdown":"https://secwatch.observer/filing/0001737287-22-000039.md","text":"https://secwatch.observer/filing/0001737287-22-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000039/0001737287-22-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000039/allo-20220615.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T00:56:09.295294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}